Home / Stock ratings / Healthcare Stocks / CI

Stock rating · Hospital & Medical Service Plans

The Cigna Group (CI) Stock Rating & Analysis

As of November 20, 2026, MELANY rates The Cigna Group 58 out of 100 (Very Promising). Its highest factor score is valuation at 87, and its lowest is catalyst setup at 24.

MELANY ratingRated 2026-11-20

CI · composite score

58/100
Very Promising
Nov 20
Rating date
Live price in the app →
Quality44
Momentum51
Risk-adjusted55
Source basis SEC filings and live market dataDated snapshot

About The Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy operations, substantially expanded by its 2018 merger with Express Scripts, are sold mostly to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with the major insurer Centene.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why CI scores 58/100

CI's 8 factor scores run from 24 to 87, and 2 of them sit above its composite of 58. Here is how CI breaks down.

Valuation87/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • P/E 11.9x vs sector 22.0x median
  • Forward P/E 8.1x, earnings growth accelerating
  • PEG ratio 0.70 (< 1 = undervalued)
Business quality44/100

Margins, returns on capital, and balance-sheet strength.

Price momentum51/100

Direction and relative strength of the recent share-price trend.

Earnings track record52/100

History of beating or missing estimates, and where estimates are heading.

Analyst sentiment73/100

What Wall Street price targets and revisions are signalling.

  • Analyst targets 27% upside
Catalyst setup24/100

Near-term events that could move the stock.

Risk-adjusted profile55/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How CI compares

As of November 20, 2026, The Cigna Group is tied for 14th of 20 in Healthcare Stocks, where the average score is 62.

All stock rating pages.

Key risks for CI

  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

The Cigna Group sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds CI's momentum and catalyst factors above.

CI trade plan (Pro)

MELANY has a full position plan for The Cigna Group: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates CI

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. The Cigna Group's 58/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about CI

Is The Cigna Group (CI) a buy?

As of 2026-11-20, MELANY rated The Cigna Group Very Promising with a composite score of 58/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does CI rank against similar companies?

As of November 20, 2026, The Cigna Group is tied for 14th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).

Should I buy The Cigna Group stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates The Cigna Group (CI) Very Promising with a composite of 58/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the CI stock price forecast?

MELANY does not publish price targets or forecasts for CI. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 58/100 across eight factors for The Cigna Group, and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for CI as of 2026-11-20: its analyst sentiment factor is 73/100 (Analyst targets 27% upside), and its price momentum factor is 51/100.

Is CI stock overvalued or undervalued?

MELANY's valuation factor currently reads 87/100 for The Cigna Group, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CI's read.

What price should I buy CI at?

Rather than chasing the current price, MELANY computes a smart entry zone for CI: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying CI stock?

The top risks MELANY currently flags for The Cigna Group: Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is The Cigna Group a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 44/100 for The Cigna Group, and earnings track record, at 52/100. The 58/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will CI stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 51/100 for CI right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this CI rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores CI as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, CI included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.